Skip to main content

Table 3 Tumor response to axitinib in combination with radiotherapy (n = 9)

From: Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial

  Overall response RT in-field response
Complete response (CR) 3 (33.3%) 4 (44.4%)
Partial response (PR) 3 (33.3%) 3 (33.3%)
Stable disease (SD) 0 (0%) 0 (0%)
Progressive disease (PD) 3 (33.3%) 2 (22.2%)
Response rate (CR + PR) 6 (66.7%) 7 (77.8%)